BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Fitzsimmons SC, Burkhart GA, Borowitz D, Grand RJ, Hammerstrom T, Durie PR, Lloyd-still JD, Lowenfels AB. High-Dose Pancreatic-Enzyme Supplements and Fibrosing Colonopathy in Children with Cystic Fibrosis. N Engl J Med 1997;336:1283-9. [DOI: 10.1056/nejm199705013361803] [Cited by in Crossref: 194] [Cited by in F6Publishing: 34] [Article Influence: 8.1] [Reference Citation Analysis]
Number Citing Articles
1 Tomasik PJ, Wędrychowicz A, Rogatko I, Zając A, Fyderek K, Sztefko K. Gastric lipase secretion in children with gastritis. Nutrients 2013;5:2924-32. [PMID: 23899880 DOI: 10.3390/nu5082924] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
2 Waldhausen JHT, Richards M. Meconium Ileus. Clin Colon Rectal Surg 2018;31:121-6. [PMID: 29487495 DOI: 10.1055/s-0037-1609027] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
3 Borowitz D, Robinson KA, Rosenfeld M, Davis SD, Sabadosa KA, Spear SL, Michel SH, Parad RB, White TB, Farrell PM, Marshall BC, Accurso FJ; Cystic Fibrosis Foundation. Cystic Fibrosis Foundation evidence-based guidelines for management of infants with cystic fibrosis. J Pediatr 2009;155:S73-93. [PMID: 19914445 DOI: 10.1016/j.jpeds.2009.09.001] [Cited by in Crossref: 223] [Cited by in F6Publishing: 158] [Article Influence: 20.3] [Reference Citation Analysis]
4 Shandro BM, Nagarajah R, Poullis A. Challenges in the management of pancreatic exocrine insufficiency. World J Gastrointest Pharmacol Ther 2018;9:39-46. [PMID: 30397535 DOI: 10.4292/wjgpt.v9.i5.39] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 5] [Article Influence: 3.3] [Reference Citation Analysis]
5 Krishnamurty DM, Rabiee A, Jagannath SB, Andersen DK. Delayed release pancrelipase for treatment of pancreatic exocrine insufficiency associated with chronic pancreatitis. Ther Clin Risk Manag 2009;5:507-20. [PMID: 19707261 DOI: 10.2147/tcrm.s3196] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
6 Lee J, Ip W, Durie P. Is fibrosing colonopathy an immune mediated disease? Arch Dis Child 1997;77:66-70. [PMID: 9279159 DOI: 10.1136/adc.77.1.66] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 0.5] [Reference Citation Analysis]
7 Konstan MW, Borowitz D, Mayer-Hamblett N, Milla C, Hendeles L, Murray S, Kronmal RA, Casey S, Rose LM, Morgan WJ, Ramsey BW. Study design considerations for evaluating the efficacy and safety of pancreatic enzyme replacement therapy in patients with cystic fibrosis. Clin Investig (Lond) 2013;3:731-41. [PMID: 25132954 DOI: 10.4155/cli.13.63] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
8 Goulart RA, Barbalho SM, Gasparini RG, de Carvalho AC. Facing Terminal Ileitis: Going Beyond Crohn's Disease. Gastroenterology Res 2016;9:1-9. [PMID: 27785317 DOI: 10.14740/gr698w] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
9 Singh VK, Haupt ME, Geller DE, Hall JA, Quintana Diez PM. Less common etiologies of exocrine pancreatic insufficiency. World J Gastroenterol. 2017;23:7059-7076. [PMID: 29093615 DOI: 10.3748/wjg.v23.i39.7059] [Cited by in CrossRef: 42] [Cited by in F6Publishing: 28] [Article Influence: 14.0] [Reference Citation Analysis]
10 Fieker A, Philpott J, Armand M. Enzyme replacement therapy for pancreatic insufficiency: present and future. Clin Exp Gastroenterol. 2011;4:55-73. [PMID: 21753892 DOI: 10.2147/ceg.s17634] [Cited by in Crossref: 13] [Cited by in F6Publishing: 29] [Article Influence: 1.3] [Reference Citation Analysis]
11 Terheggen G, Dieninghoff D, Rietschel E, Drebber U, Kruis W, Leifeld L. Successful non-invasive treatment of stricturing fibrosing colonopathy in an adult patient. Eur J Med Res. 2011;16:411-414. [PMID: 22024442 DOI: 10.1186/2047-783x-16-9-411] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
12 Littlewood JM. Update on intestinal strictures. J R Soc Med 1999;92 Suppl 37:41-9. [PMID: 10472252 DOI: 10.1177/014107689909237s08] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
13 Layer P, Keller J, Lankisch PG. Pancreatic enzyme replacement therapy. Curr Gastroenterol Rep. 2001;3:101-108. [PMID: 11276376 DOI: 10.1007/s11894-001-0005-8] [Cited by in Crossref: 52] [Cited by in F6Publishing: 48] [Article Influence: 2.9] [Reference Citation Analysis]
14 Kimura RE, Arango V, Lloyd-Still J. Indomethacin and pancreatic enzymes synergistically damage intestine of rats. Dig Dis Sci 1998;43:2322-32. [PMID: 9790472 DOI: 10.1023/a:1026691227845] [Cited by in Crossref: 11] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
15 Gelfond D, Heltshe SL, Skalland M, Heubi JE, Kloster M, Leung DH, Ramsey BW, Borowitz D; BONUS Study Investigators. Pancreatic Enzyme Replacement Therapy Use in Infants With Cystic Fibrosis Diagnosed by Newborn Screening. J Pediatr Gastroenterol Nutr 2018;66:657-63. [PMID: 29176494 DOI: 10.1097/MPG.0000000000001829] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 5.5] [Reference Citation Analysis]
16 Pezzilli R, Andriulli A, Bassi C, Balzano G, Cantore M, Delle Fave G, Falconi M; Exocrine Pancreatic Insufficiency collaborative (EPIc) Group. Exocrine pancreatic insufficiency in adults: a shared position statement of the Italian Association for the Study of the Pancreas. World J Gastroenterol 2013;19:7930-46. [PMID: 24307787 DOI: 10.3748/wjg.v19.i44.7930] [Cited by in CrossRef: 66] [Cited by in F6Publishing: 54] [Article Influence: 9.4] [Reference Citation Analysis]
17 Birindelli A, Tugnoli G, Beghelli D, Siciliani A, Biscardi A, Bertarelli C, Selleri S, Lombardi R, Di Saverio S. Emergency laparoscopic ileo-colic resection and primary intracorporeal anastomosis for Crohn's acute ileitis with free perforation and faecal peritonitis: first ever reported laparoscopic treatment. Springerplus 2016;5:16. [PMID: 26759755 DOI: 10.1186/s40064-015-1619-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
18 Lindkvist B. Diagnosis and treatment of pancreatic exocrine insufficiency. World J Gastroenterol. 2013;19:7258-7266. [PMID: 24259956 DOI: 10.3748/wjg.v19.i42.7258] [Cited by in CrossRef: 91] [Cited by in F6Publishing: 66] [Article Influence: 13.0] [Reference Citation Analysis]
19 Durie P, Kalnins D, Ellis L. Uses and abuses of enzyme therapy in cystic fibrosis. J R Soc Med 1998;91 Suppl 34:2-13. [PMID: 9709382 DOI: 10.1177/014107689809134s02] [Cited by in Crossref: 21] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
20 Stallings VA, Mondick JT, Schall JI, Barrett JS, Wilson M, Mascarenhas MR. Diagnosing malabsorption with systemic lipid profiling: pharmacokinetics of pentadecanoic acid and triheptadecanoic acid following oral administration in healthy subjects and subjects with cystic fibrosis. Int J Clin Pharmacol Ther 2013;51:263-73. [PMID: 23357842 DOI: 10.5414/CP201793] [Cited by in Crossref: 16] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
21 Keller J, Layer P. Pancreatic Enzyme Supplementation Therapy. Curr Treat Options Gastroenterol. 2003;6:369-374. [PMID: 12954143 DOI: 10.1007/s11938-003-0039-0] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 1.2] [Reference Citation Analysis]
22 Haack A, Aragão GG, Novaes MR. Pathophysiology of cystic fibrosis and drugs used in associated digestive tract diseases. World J Gastroenterol 2013;19:8552-61. [PMID: 24379572 DOI: 10.3748/wjg.v19.i46.8552] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 12] [Article Influence: 2.1] [Reference Citation Analysis]
23 Rumman N, Sultan M, El-Chammas K, Goh V, Salzman N, Quintero D, Werlin S. Calprotectin in cystic fibrosis. BMC Pediatr 2014;14:133. [PMID: 24885444 DOI: 10.1186/1471-2431-14-133] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
24 Lloyd-Still JD, Beno DW, Kimura RM. Cystic fibrosis colonopathy. Curr Gastroenterol Rep 1999;1:231-7. [PMID: 10980955 DOI: 10.1007/s11894-999-0040-4] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
25 Struyvenberg MR, Martin CR, Freedman SD. Practical guide to exocrine pancreatic insufficiency - Breaking the myths. BMC Med. 2017;15:29. [PMID: 28183317 DOI: 10.1186/s12916-017-0783-y] [Cited by in Crossref: 50] [Cited by in F6Publishing: 36] [Article Influence: 12.5] [Reference Citation Analysis]
26 Waljee AK, Dimagno MJ, Wu BU, Schoenfeld PS, Conwell DL. Systematic review: pancreatic enzyme treatment of malabsorption associated with chronic pancreatitis. Aliment Pharmacol Ther. 2009;29:235-246. [PMID: 19035969 DOI: 10.1111/j.1365-2036.2008.03885.x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 2.0] [Reference Citation Analysis]
27 Baker SS. Delayed release pancrelipase for the treatment of pancreatic exocrine insufficiency associated with cystic fibrosis. Ther Clin Risk Manag 2008;4:1079-84. [PMID: 19209287 DOI: 10.2147/tcrm.s3123] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
28 Meyer JH, Lake R, Elashoff JD. Postcibal gastric emptying of pancreatin pellets: effects of dose and meal oil. Dig Dis Sci. 2001;46:1846-1852. [PMID: 11575435 DOI: 10.1023/a:1010666510755] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
29 Littlewood JM, Wolfe SP. Control of malabsorption in cystic fibrosis. Paediatr Drugs 2000;2:205-22. [PMID: 10937471 DOI: 10.2165/00128072-200002030-00005] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 1.1] [Reference Citation Analysis]
30 Bechtold ML, McClave SA, Palmer LB, Nguyen DL, Urben LM, Martindale RG, Hurt RT. The pharmacologic treatment of short bowel syndrome: new tricks and novel agents. Curr Gastroenterol Rep 2014;16:392. [PMID: 25052938 DOI: 10.1007/s11894-014-0392-2] [Cited by in Crossref: 16] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
31 Lowdon J, Goodchild MC, Ryley HC, Doull IJ. Maintenance of growth in cystic fibrosis despite reduction in pancreatic enzyme supplementation. Arch Dis Child 1998;78:377-8. [PMID: 9623407 DOI: 10.1136/adc.78.4.377] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
32 Pathanki AM, Attard JA, Bradley E, Powell-Brett S, Dasari BVM, Isaac JR, Roberts KJ, Chatzizacharias NA. Pancreatic exocrine insufficiency after pancreaticoduodenectomy: Current evidence and management. World J Gastrointest Pathophysiol 2020;11:20-31. [PMID: 32318312 DOI: 10.4291/wjgp.v11.i2.20] [Cited by in CrossRef: 2] [Article Influence: 2.0] [Reference Citation Analysis]
33 Rowe SM, Borowitz DS, Burns JL, Clancy JP, Donaldson SH, Retsch-Bogart G, Sagel SD, Ramsey BW. Progress in cystic fibrosis and the CF Therapeutics Development Network. Thorax 2012;67:882-90. [PMID: 22960984 DOI: 10.1136/thoraxjnl-2012-202550] [Cited by in Crossref: 44] [Cited by in F6Publishing: 33] [Article Influence: 4.9] [Reference Citation Analysis]
34 Sarner M. Treatment of pancreatic exocrine deficiency. World J Surg. 2003;27:1192-1195. [PMID: 14534818 DOI: 10.1007/s00268-003-7237-8] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]